

Ein Quantensprung in der Therapie entzündlicher Dermatosen

Literatur Psoriasis vulgaris

- [1] Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008;371(9625):1665-1674.
- [2] Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008;371(9625):1675-1684.
- [3] Lebwohl M, Blauvelt A, Paul C et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). *J. Am. Acad. Dermatol.* 2018; 79: 266-76.e5.
- [4] Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). *J. Am. Acad. Dermatol.* 2017; 77: 855-62.
- [5] Reich K, Warren RB, Iversen L et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. *Br. J. Dermatol.* 2019.
- [6] Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica* 1978; 157: 238-44.
- [7] Sbidian E, Chaimani A, Afach S et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst. Rev.* 2020; 1: Cd011535.
- [8] Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J. Am. Acad. Dermatol.* 2015; 73: 37-49.
- [9] Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. *Br. J. Dermatol.* 2016; 175: 273-86.
- [10] Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects. *Trends Pharmacol. Sci.* 2018; 39: 1- 12.
- [11] Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J. Am. Acad. Dermatol.* 1993; 28: 466-9.
- [12] Tying S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. *Arch. Dermatol.* 2007; 143: 719-26.

- [13] Menter A, Warren RB, Langley RG et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). *J. Eur. Acad. Dermatol. Venereol.* 2017; 31: 1686-92.
- [14] Deodhar A, Mease PJ, McInnes IB et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. *Arthritis Res. Ther.* 2019; 21: 111.
- [15] Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet* 2018; 392: 650-61..
- [16] Gerdes S, Thaci D, Griffiths CEM et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. *J. Eur. Acad. Dermatol. Venereol.* 2018; 32: 420-7.
- [17] Blauvelt A, Lacour JP, Fowler JF, Jr. et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. *Br. J. Dermatol.* 2018; 179: 623-31.
- [18] Reich K, Armstrong AW, Langley RG et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. *Lancet* 2019; 394: 831-9.
- [19] Papp KA, Griffiths CE, Gordon K et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. *Br. J. Dermatol.* 2013; 168: 844-54.
- [20] Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. *Arch. Dermatol. Res.* 2010; 302: 531-8.
- [21] Maza A, Montaudie H, Sbidian E et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. *J. Eur. Acad. Dermatol. Venereol.* 2011; 25 Suppl 2: 19-27.
- [22] Clowse ME, Förger F, Hwang C et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicenter, pharmacokinetic study. *Ann. Rheum. Dis.* 2017; 76: 1890-6.

Literatur Atopische Dermatitis

- [1] Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet.* 2006 Apr;38(4):441-6.
- [2] Simpson EL, Bieber T, Guttman-Yassky E, et al.; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med.* 2016 Dec 15;375(24):2335-2348.
- [3] Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp Dermatol* 10:11-18. *Experimental Dermatology* 10(1):11-18.
- [4] Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT®) using a longitudinal survey of biologic-treated patients with atopic dermatitis. *BMC Dermatol.* 2019 Nov 6;19(1):15.

- [5] Willemze R, van Vloten WA, Hermans J, Damsteeg MJ, Meijer CJ. Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. *Invest Dermatol*. 1983 Nov;81(5):392-7.
- [6] www.awmf.org/uploads/tx_szleitlinien/013027l_S2k_Neurodermitis
- [7] Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2020 Jul 25;396(10246):255-266.
- [8] Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020 Nov;83(5):1282-1293.
- [9] Silverberg JL, Toth D, Bieber T, et al.; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. *Br J Dermatol*. 2021 Mar;184(3):450-463.
- [10] Reich K, Kabashima K, Peris K, et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol*. 2020 Dec 1;156(12):1333-1343.
- [11] Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. *J Eur Acad Dermatol Venereol*. 2020 Jan;34(1):142-152.
- [12] Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. *J Immunol* 2010;184:5298-307.
- [13] Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. *Br J Dermatol* 2018;179:54-62.
- [14] Parmentier JM, Voss J, Graff C. et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). *BMC Rheumatol* 2, 23 (2018).
- [15] Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. *Am J Clin Dermatol*. 2020 Dec;21(6):783-798.
- [16] Guttman-Yassky E. Oral presentation at EADV 2020, D3T03.4B, presented at the European Academy of Dermatology and Venereology virtual meeting 2020.
- [17] Reich K. D3T03.4C, presented at the European Academy of Dermatology and Venereology virtual meeting 2020.
- [18] Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet* 2017 Jun 10;389(10086):2287-2303.
- [19] Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. for ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br J Dermatol*. 2021 Mar;184(3):437-449.

- [20] Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. *Br J Dermatol*. 2020 Aug;183(2):242-255.
- [21] Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2021. VOLUME 397, ISSUE 10290, P2169-2181.
- [22] Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*. 2021 Jun 5;397(10290):2151-2168.